The phase II/III MAHOGANY trial including three arms, margetuximab plus retifanlimab (anti-PD-1 mAb) with or without chemotherapy and margetuximab plus tebotelimab (anti-PD-1 and anti-LAG-3 bispecific mAb) with chemotherapy in first-line unresectable metastatic/locally advanced GEJ adenocarcinoma is ongoing (NCT04082364) (27). This evidence concerns the gene LAG3 and gastroesophageal junction adenocarcinoma.